Immunome Inc. Reports Board and Compensation Changes
Ticker: IMNM · Form: 8-K · Filed: Jan 23, 2025 · CIK: 1472012
| Field | Detail |
|---|---|
| Company | Immunome Inc. (IMNM) |
| Form Type | 8-K |
| Filed Date | Jan 23, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $100,000, $300,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-changes
Related Tickers: IMNP
TL;DR
Immunome Inc. filed an 8-K detailing board changes and executive comp adjustments.
AI Summary
Immunome Inc. announced on January 21, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of directors and the election of new ones, alongside adjustments to compensatory plans for certain officers. Specific financial details or names of individuals involved in these changes were not provided in this excerpt.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing primarily concerns corporate governance and executive compensation, which typically carries a lower immediate risk compared to financial distress or major operational shifts.
Key Players & Entities
- Immunome Inc. (company) — Registrant
- January 21, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Bothell, WA (location) — Principal executive offices
FAQ
What specific items are covered under the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' section?
This section of the 8-K filing covers the departure of directors, the election of new directors, and details regarding the compensatory arrangements for certain officers of Immunome Inc.
When was the earliest event reported in this Form 8-K?
The earliest event reported in this Form 8-K was on January 21, 2025.
What is the principal executive office address for Immunome Inc.?
The principal executive offices of Immunome Inc. are located at 18702 N. Creek Parkway, Suite 100, Bothell, WA 98011.
What is the SIC code for Immunome Inc.?
The Standard Industrial Classification (SIC) code for Immunome Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the fiscal year end for Immunome Inc.?
Immunome Inc.'s fiscal year ends on December 31.
Filing Stats: 567 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-01-23 16:01:24
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IMNM The Nasdaq
- $100,000 — Company will pay Mr. Rosett a one-time $100,000 cash relocation bonus within 10 days of
- $300,000 — also be entitled to receive a one-time $300,000 cash bonus (the "Housing Bonus"), subje
Filing Documents
- tm254188d1_8k.htm (8-K) — 27KB
- tm254188d1_ex10-1.htm (EX-10.1) — 10KB
- 0001104659-25-005594.txt ( ) — 210KB
- immu-20250121.xsd (EX-101.SCH) — 3KB
- immu-20250121_lab.xml (EX-101.LAB) — 33KB
- immu-20250121_pre.xml (EX-101.PRE) — 22KB
- tm254188d1_8k_htm.xml (XML) — 4KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibit Number Descriptions 10.1 Relocation Offer Letter dated January 20, 2025, by and between the Company and Max Rosett. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. IMMUNOME, INC. Date: January 23, 2025 By: /s/ Clay Siegall Clay Siegall, Ph.D. President and Chief Executive Officer